BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32632664)

  • 1. CD66b
    Horzum U; Yoyen-Ermis D; Taskiran EZ; Yilmaz KB; Hamaloglu E; Karakoc D; Esendagli G
    Cancer Immunol Immunother; 2021 Jan; 70(1):75-87. PubMed ID: 32632664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets.
    Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S
    Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893
    [No Abstract]   [Full Text] [Related]  

  • 3. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.
    Poschke I; Mougiakakos D; Hansson J; Masucci GV; Kiessling R
    Cancer Res; 2010 Jun; 70(11):4335-45. PubMed ID: 20484028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.
    Höchst B; Schildberg FA; Sauerborn P; Gäbel YA; Gevensleben H; Goltz D; Heukamp LC; Türler A; Ballmaier M; Gieseke F; Müller I; Kalff J; Kurts C; Knolle PA; Diehl L
    J Hepatol; 2013 Sep; 59(3):528-35. PubMed ID: 23665041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer.
    Tavukcuoglu E; Horzum U; Yanik H; Uner A; Yoyen-Ermis D; Nural SK; Aydin B; Sokmensuer C; Karakoc D; Yilmaz KB; Hamaloglu E; Esendagli G
    Eur J Immunol; 2020 Dec; 50(12):2067-2074. PubMed ID: 32691408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion of CD10
    Fraccarollo D; Neuser J; Möller J; Riehle C; Galuppo P; Bauersachs J
    Elife; 2021 Jul; 10():. PubMed ID: 34289931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2).
    Soler DC; Kerstetter-Fogle A; Young AB; Rayman P; Finke JH; Debanne SM; Cooper KD; Barnholtz-Sloan J; Sloan AE; McCormick TS
    Mol Immunol; 2022 Feb; 142():1-10. PubMed ID: 34953280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
    J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck.
    Chikamatsu K; Sakakura K; Toyoda M; Takahashi K; Yamamoto T; Masuyama K
    Cancer Sci; 2012 Jun; 103(6):976-83. PubMed ID: 22360618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi) /CD16(neg) monocytes: Expansion of CD14(hi) /CD16(pos) and contraction of CD14(lo) /CD16(pos) monocytes in acute liver failure.
    Abeles RD; McPhail MJ; Sowter D; Antoniades CG; Vergis N; Vijay GK; Xystrakis E; Khamri W; Shawcross DL; Ma Y; Wendon JA; Vergani D
    Cytometry A; 2012 Oct; 81(10):823-34. PubMed ID: 22837127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.
    Mao Y; Poschke I; Wennerberg E; Pico de Coaña Y; Egyhazi Brage S; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
    Cancer Res; 2013 Jul; 73(13):3877-87. PubMed ID: 23633486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.
    Huang A; Zhang B; Wang B; Zhang F; Fan KX; Guo YJ
    Cancer Immunol Immunother; 2013 Sep; 62(9):1439-51. PubMed ID: 23760662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
    Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
    Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulatory effects of CD14+CD16++ monocytes on CD14++CD16- monocytes: a possible explanation of monocyte alterations in systemic lupus erythematosus.
    Burbano C; Vasquez G; Rojas M
    Arthritis Rheumatol; 2014 Dec; 66(12):3371-81. PubMed ID: 25168844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells.
    Schilling B; Sucker A; Griewank K; Zhao F; Weide B; Görgens A; Giebel B; Schadendorf D; Paschen A
    Int J Cancer; 2013 Oct; 133(7):1653-63. PubMed ID: 23526263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded CD14
    Zhang R; Shi J; Zhang R; Ni J; Habtezion A; Wang X; Hu G; Xue J
    J Immunol; 2019 May; 202(9):2578-2584. PubMed ID: 30894427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
    Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
    J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
    Zhang B; Wang Z; Wu L; Zhang M; Li W; Ding J; Zhu J; Wei H; Zhao K
    PLoS One; 2013; 8(2):e57114. PubMed ID: 23437326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma.
    Yuan XK; Zhao XK; Xia YC; Zhu X; Xiao P
    J Int Med Res; 2011; 39(4):1381-91. PubMed ID: 21986138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.
    Safarzadeh E; Mohammadi A; Mansoori B; Duijf PHG; Hashemzadeh S; Khaze V; Kazemi T; Derakhshani A; Silvestris N; Baradaran B
    Front Immunol; 2020; 11():613215. PubMed ID: 33679700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.